Which treatment modality should we choose for advanced hepatocellular carcinoma?
作者信息
Kim Do Young
出版信息
Korean J Hepatol. 2010 Dec;16(4):353-4. doi: 10.3350/kjhep.2010.16.4.353.
Abstract
摘要
相似文献
1
Which treatment modality should we choose for advanced hepatocellular carcinoma?
Korean J Hepatol. 2010 Dec;16(4):353-4. doi: 10.3350/kjhep.2010.16.4.353.
2
Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
Asia Pac J Clin Oncol. 2012 Jun;8(2):111-4. doi: 10.1111/j.1743-7563.2012.01551.x.
3
Major achievements in hepatocellular carcinoma.
Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0.
4
5
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Oncology. 2018;94(4):215-222. doi: 10.1159/000486483. Epub 2018 Feb 9.
6
The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
BMC Cancer. 2012 Jun 21;12:263. doi: 10.1186/1471-2407-12-263.
7
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.
8
[Multimodality treatment for hepatocellular carcinoma].
Internist (Berl). 2010 Nov;51(11):1374-81. doi: 10.1007/s00108-010-2673-7.
9
10
Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
J Gastrointest Cancer. 2010 Jun;41(2):149-52. doi: 10.1007/s12029-010-9146-z.
本文引用的文献
1
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
Korean J Hepatol. 2010 Dec;16(4):355-61. doi: 10.3350/kjhep.2010.16.4.355.
2
Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review.
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):460-7. doi: 10.1016/j.ijrobp.2010.06.010. Epub 2010 Oct 1.
3
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
Cancer Chemother Pharmacol. 2010 Jan;65(2):373-82. doi: 10.1007/s00280-009-1126-2. Epub 2009 Sep 18.
4
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
5
Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis.
Cancer. 2008 Sep 1;113(5):995-1003. doi: 10.1002/cncr.23684.
6
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Cancer. 2007 Jul 1;110(1):129-37. doi: 10.1002/cncr.22759.
7
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.
Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25. doi: 10.1007/s00270-006-0062-3.
8
Management of hepatocellular carcinoma.
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
9
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8. doi: 10.1093/jnci/dji315.
10
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Cancer. 2002 Aug 1;95(3):588-95. doi: 10.1002/cncr.10694.
Zotero 插件